IRegained

IRegained operates at the intersection of medical devices, digital health and home-based neurorehabilitation. Its MyHand™ System combines mechatronic hardware for hand movement training with digital therapy software, interactive exercises, assessment tools and clinician-facing remote monitoring. That integrated approach distinguishes the company’s stated product offering from a software-only rehabilitation tool, while its home-use design targets therapy beyond clinic visits. Its focus is comparatively specific: helping people with hand-function impairments associated with stroke or traumatic brain injury, using repeated task-oriented movement, sensory feedback and neuroplasticity-based protocols. The company describes 16 proprietary function-oriented protocols, customizable exercises and games, and progress analytics; its website materials also report clinical validation across multiple studies. The available comparable-company entries do not identify independent competitors, so a named competitor comparison or relative market-share assessment is not supportable. The company’s disclosed scale indicators are an employee band of 11–50 and $1,909,923 in total funding across seven rounds, including grants and non-equity assistance as well as seed and convertible-note financing. These facts place it among smaller, early-stage digital rehabilitation and medical-device businesses, rather than establishing commercial scale or market leadership.

IRegained was founded on Dec 16, 2016 and has developed a focused rehabilitation product offering around the MyHand™ System. Its financing history shows several early stages: a $194,751 pre-seed round in 2018, a $210,559 seed round in 2019, grant funding in 2020, additional convertible-note and non-equity assistance financing in 2020–2021, and a $250,000 seed round on Jan 1, 2022. Across seven listed rounds, the aggregate is $1,909,923. Product capabilities described include a portable mechatronic device, digital protocols, interactive games, patient assessment and remote clinician tools. A patent publication dated Feb 15, 2023 adds evidence of continued technical development, while coverage in March 2025 placed IRegained among health-care innovators featured in an accelerator story. Hiring needs span mechatronics, embedded systems, software and clinical research, suggesting the company’s growth priorities combine engineering with clinical work.